Amundi Grows Position in Glaukos Corporation $GKOS

Amundi grew its stake in Glaukos Corporation (NYSE:GKOS) by 5.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 239,279 shares of the medical instruments supplier’s stock after buying an additional 11,989 shares during the quarter. Amundi’s holdings in Glaukos were worth $24,796,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in GKOS. Nuveen LLC purchased a new stake in Glaukos in the 1st quarter worth approximately $31,474,000. Ehrlich Financial Group bought a new position in shares of Glaukos in the second quarter worth approximately $1,034,000. Royal Bank of Canada increased its stake in shares of Glaukos by 103.2% in the first quarter. Royal Bank of Canada now owns 228,249 shares of the medical instruments supplier’s stock worth $22,464,000 after purchasing an additional 115,939 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Glaukos in the first quarter worth $307,000. Finally, LPL Financial LLC raised its position in shares of Glaukos by 25.1% during the 1st quarter. LPL Financial LLC now owns 15,775 shares of the medical instruments supplier’s stock valued at $1,553,000 after purchasing an additional 3,163 shares during the period. Institutional investors own 99.04% of the company’s stock.

Glaukos Price Performance

GKOS stock opened at $108.54 on Thursday. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $163.71. The firm has a market capitalization of $6.23 billion, a P/E ratio of -70.48 and a beta of 0.69. The company has a fifty day simple moving average of $90.84 and a two-hundred day simple moving average of $92.58. The company has a quick ratio of 4.47, a current ratio of 5.20 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.11. The firm had revenue of $133.54 million for the quarter, compared to analysts’ expectations of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The business’s revenue was up 38.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.28) EPS. Analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Insider Activity at Glaukos

In related news, COO Joseph E. Gilliam sold 19,340 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $90.00, for a total transaction of $1,740,600.00. Following the sale, the chief operating officer owned 92,366 shares in the company, valued at approximately $8,312,940. This represents a 17.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Alex R. Thurman sold 315 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total value of $33,075.00. Following the completion of the sale, the chief financial officer owned 50,488 shares of the company’s stock, valued at approximately $5,301,240. This represents a 0.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 5.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

GKOS has been the subject of several recent analyst reports. Needham & Company LLC upped their target price on shares of Glaukos from $117.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday. Truist Financial set a $120.00 price objective on Glaukos in a research note on Thursday, October 30th. Wells Fargo & Company increased their target price on Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. Stifel Nicolaus set a $115.00 target price on shares of Glaukos in a report on Monday, October 27th. Finally, BTIG Research raised their target price on shares of Glaukos from $104.00 to $116.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.69.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.